The authors wish to make the following corrections to this paper [1].
In Figure 1, all “SGLT-2i” should be replaced by “SU”. Correspondingly, in the figure legend, the definition of “SGLT-2i” should be removed.
Figure 1.
Flow chart of the sample selection process. DM, diabetes mellitus; DPP-4i, dipeptidyl-peptidase IV inhibitor; N, number; SU, sulfonylurea.
After correction, Figure 1 should be displayed as below:
The authors would like to apologize for any inconvenience caused to the readers by these changes.
Reference
- 1.Kim Y.G., Jeon J., Kim H., Kim D., Lee K.W., Moon S., Han S. Risk of dementia in older patients with type 2 diabetes on dipeptidyl-peptidase IV inhibitors versus sulfonylureas: A real-world population-based cohort study. J. Clin. Med. 2019;8:28. doi: 10.3390/jcm8010028. [DOI] [PMC free article] [PubMed] [Google Scholar]